Attached files

file filename
EX-21 - EX-21 - Flexion Therapeutics Incd134391dex21.htm
EX-31.2 - EX-31.2 - Flexion Therapeutics Incd134391dex312.htm
EX-10.6 - EX-10.6 - Flexion Therapeutics Incd134391dex106.htm
EX-32.1 - EX-32.1 - Flexion Therapeutics Incd134391dex321.htm
EX-31.1 - EX-31.1 - Flexion Therapeutics Incd134391dex311.htm
EX-23.1 - EX-23.1 - Flexion Therapeutics Incd134391dex231.htm
EX-10.21 - EX-10.21 - Flexion Therapeutics Incd134391dex1021.htm
10-K - FORM 10-K - Flexion Therapeutics Incd134391d10k.htm
EX-10.20 - EX-10.20 - Flexion Therapeutics Incd134391dex1020.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Frederick W. Driscoll, Chief Financial Officer of Flexion Therapeutics, Inc. (the “Registrant”), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based upon my knowledge:

 

(1) this Annual Report on Form 10-K of the Registrant, to which this certification is attached as an exhibit (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and

 

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

 

Date: March 11, 2016     /s/ Frederick W. Driscoll
    Frederick W. Driscoll
    Chief Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.